公开(公告)号：US11749394B2

公开(公告)日：2023-09-05

申请号：US17374315

申请日：2021-07-13

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kameswara Rao Kuchimanchi ,  Alexandra Loew-Baselli ,  Gerald Spotts ,  Myungshin Oh ,  Michael Don Hale ,  Martin Wolfsegger

IPC: G16H20/17 ,  G16H50/70 ,  G16H50/50 ,  G16H50/20 ,  G16C20/30 ,  G16C20/50 ,  G16C20/70 ,  A61P7/04 ,  A61K49/00 ,  G06N7/01

CPC classification number: G16H20/17 ,  G16C20/30 ,  G16H50/20 ,  G16H50/50 ,  G16H50/70 ,  A61K49/0004 ,  A61P7/04 ,  G06N7/01 ,  G16C20/50 ,  G16C20/70

Abstract: Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.

公开(公告)号：US11731983B2

公开(公告)日：2023-08-22

申请号：US17349584

申请日：2021-06-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Kazuhiro Miwa

IPC: C07D495/04 ,  C07D333/38 ,  C07D409/12

CPC classification number: C07D495/04 ,  C07D333/38 ,  C07D409/12

Abstract: The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrimidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1′-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.

公开(公告)号：US20230257708A1

公开(公告)日：2023-08-17

申请号：US18164989

申请日：2023-02-06

Applicant: National Cancer Center Japan ,  Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Tetsuya Nakatsura ,  Toshiaki Yoshikawa ,  Yasushi Uemura ,  Kyoko Fukuda ,  Shin Kaneko ,  Atsutaka Minagawa ,  Yoshiaki Kassai ,  Atsushi Matsuda

IPC: C12N5/0783 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C12N15/86

CPC classification number: C12N5/0638 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C12N15/86 ,  C12N2506/45

Abstract: Provided is a T cell receptor containing, as α chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as β chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor containing, as an α chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 13 to 15, as β chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 16 to 18, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02.

公开(公告)号：US20230257338A1

公开(公告)日：2023-08-17

申请号：US17900412

申请日：2022-08-31

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoru Matsumoto ,  Yoshimasa Omori ,  Masahiro Mineno ,  Yasutaka Hoashi

IPC: C07C69/533 ,  A61K9/16 ,  C12N15/113

CPC classification number: C07C69/533 ,  A61K9/1617 ,  C12N15/113

Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.

公开(公告)号：US11696893B2

公开(公告)日：2023-07-11

申请号：US16629096

申请日：2018-07-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Hiroyuki Fujii ,  Akira Suzuki

IPC: A61K9/14 ,  A61K9/00 ,  A61K9/20 ,  A61K31/4439 ,  A61K47/12

CPC classification number: A61K9/14 ,  A61K9/0056 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/4439 ,  A61K47/12

Abstract: The present invention aims to provide a preparation expected to improve the bitter taste of an organic acid salt of vonoprazan and permit rapid dissolution of the organic acid salt of vonoprazan after administration.
The present invention provides a preparation containing fine granules or granules containing (1) a core granule containing an organic acid salt of vonoprazan, (2) an intermediate layer containing the same organic acid as the organic acid forming the salt of vonoprazan in (1), or a salt thereof, and (3) a coating layer containing a water-insoluble polymer.

公开(公告)号：US20230211017A1

公开(公告)日：2023-07-06

申请号：US18145784

申请日：2022-12-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Hanspeter Rottensteiner ,  Friedrich Scheiflinger

IPC: A61K48/00 ,  A61P7/04

CPC classification number: A61K48/0066 ,  A61K48/0058 ,  A61P7/04

Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.

公开(公告)号：US20230203186A1

公开(公告)日：2023-06-29

申请号：US17810377

申请日：2022-07-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Kathleen Ann Elias ,  Gregory Landes ,  Shweta Singh ,  Wouter Korver ,  Andrew Walling Drake ,  Mary Haak-Frendscho ,  Vinay Bhaskar ,  Erin Willert

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.

公开(公告)号：US20230201227A1

公开(公告)日：2023-06-29

申请号：US18184918

申请日：2023-03-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Richard Labotka ,  Andrew Fergus

IPC: A61K31/69 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395

CPC classification number: A61K31/69 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2896 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/73

Abstract: The present disclosure relates to methods for treating cancer, or preventing cancer recurrence or progression, comprising administering a patient an anti-CD38 antibody and a proteasome inhibitor.

公开(公告)号：US11684632B2

公开(公告)日：2023-06-27

申请号：US16983310

申请日：2020-08-03

Applicant: Takeda Pharmaceutical Company Limited

Inventor： John D. Peabody, III

IPC: A61K31/7056 ,  G09B19/00 ,  A61K45/06 ,  G01N33/94

CPC classification number: A61K31/7056 ,  A61K45/06 ,  G01N33/94 ,  G09B19/00 ,  G01N2430/00 ,  G01N2800/52

Abstract: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

公开(公告)号：US20230192685A1

公开(公告)日：2023-06-22

申请号：US17927584

申请日：2021-05-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hitoaki NISHIKAWA ,  Naohiro TAYA ,  Hiroshi BANNO ,  Masatoshi YAMADA ,  Kazuki AZUMA ,  Ayaka SUZUKI

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: A method for producing a compound represented by the formula (X):




or a salt thereof and has a MALT1 inhibitory action, the said method containing a step for producing a compound a compound represented by the formula (B-2):




or a salt thereof and being characterized by comprising crystallizing a salt of a compound represented by the formula (B-1)




and an optically active organic acid.

(In the formulae, each symbol is as defined in the specification.)